Showing results (341-350 of 383) with videos related to
Sort By:
Pageof 39
Journal of Thrombosis and Thrombolysis|September 18, 2013
Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patientsHenrik Wagner, Dominick J Angiolillo, Jurrien M Ten Berg, et al.Chemical Science|February 16, 2024
Polarization of macrophages to an anti-cancer phenotype through <i>in situ</i> uncaging of a TLR 7/8 agonist using bioorthogonal nanozymesXianzhi Zhang, Yuanchang Liu, Mingdi Jiang, et al.European Journal of Clinical Pharmacology|November 6, 2009
The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjectsDavid S Small, Prajakti Kothare, Eunice Yuen, et al.Journal of the American College of Cardiology|October 23, 2012
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trialDavid Erlinge, Jurrien Ten Berg, David Foley, et al.Behavioural Brain Research|April 5, 2021
Hippocampal activation during contextual fear inhibition related to resilience in the early aftermath of traumaSanne J H van Rooij, Meghna Ravi, Timothy D Ely, et al.Clinical Cardiology|May 14, 2016
Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS TrialEmil Hagström, Matthew T Roe, Gail Hafley, et al.Plos Genetics|June 10, 2011
Pathogenic mechanism of the FIG4 mutation responsible for Charcot-Marie-Tooth disease CMT4JGuy M Lenk, Cole J Ferguson, Clement Y Chow, et al.Journal of Clinical Pharmacy and Therapeutics|September 12, 2009
Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal diseaseD S Small, R E Wrishko, C S Ernest, et al.Journal of Pediatric Hematology/Oncology|December 11, 2014
Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging studyLori Styles, Darell Heiselman, Lori E Heath, et al.Thrombosis and Haemostasis|January 10, 2014
Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery diseaseDavid Erlinge, Stefan James, Suman Duvvuru, et al.Pageof 39